GE HealthCare investigation continues after guidance cut
The Law Offices of Frank R. Cruz is investigating GE HealthCare Technologies Inc. for potential federal securities law violations. The probe follows a 13.2% drop in share price after the company cut its full-year 2026 adjusted EPS guidance to $4.80–$5.00, citing a PDx supplier recall and margin declines. Investors who suffered losses are urged to contact the firm.
*this image is generated using AI for illustrative purposes only.
The Law Offices of Frank R. Cruz continues its investigation of GE HealthCare Technologies Inc. on behalf of investors concerning possible violations of federal securities laws. The investigation focuses on the company's financial disclosures and subsequent market impact following its first-quarter 2026 earnings report.
On April 29, 2026, GE HealthCare reported its financial results for the first quarter of 2026. The company reported adjusted earnings per share of $0.99 and cut its full-year 2026 adjusted EPS guidance to a range of $4.80 to $5.00, down from prior guidance of $4.95 to $5.15.
During the earnings call, management disclosed that profit performance in the first quarter was impacted by a recall associated with a PDx supplier. Additionally, the company stated that year-over-year margin performance was affected by declines in PCS and the PDx supplier issue.
Following this news, the price of GE HealthCare shares declined by $9.01 per share, or 13.2%, to close at $59.49 per share on April 29, 2026.
Key Financial Details
| Metric | Value |
|---|---|
| Q1 2026 Adjusted EPS | $0.99 |
| Prior FY26 Guidance | $4.95 – $5.15 |
| Revised FY26 Guidance | $4.80 – $5.00 |
| Share Price Decline | $9.01 (13.2%) |
| Closing Price (April 29, 2026) | $59.49 |
Investors who purchased GE HealthCare securities and have information or questions regarding the investigation are encouraged to contact The Law Offices of Frank R. Cruz. The firm is located at 2121 Avenue of the Stars, Suite 800, Century City, California 90067, and can be reached at 310-914-5007 or via email at info@frankcruzlaw.com .
What is the estimated financial duration and total cost of the recall associated with the PDx supplier?
Will the company seek to diversify its supplier base to mitigate future risks similar to the PDx issue?
How will the margin pressure from PCS declines impact the company's long-term profitability strategy?
15
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
